year left
short interest float
checkpoint therapeut biopharmaceut compani primarili
focus develop immuno- target oncolog treatment compani lead
candid fulli human antibodi target current evalu
phase dose escal trial solid tumor posit compani plan initi
registr trial earli treatment newli diagnos high
express non-smal cell lung cancer nsclc compani secondari
asset egfr inhibitor activ egfr-activ resist
mutat current evalu dose-escal phase studi clinic
updat expect follow confirmatori phase ii studi checkpoint plan
begin phase studi compani also evalu
targeted- immuno- oncolog therapi includ parp inhibitor bet inhibitor
anti-gitr agonist anti-caix therapeut antibodi checkpoint valu proposit
primarili focus develop drug well-valid target acceler
approv establish competit price ad potenti combin
product therebi becom one-stop shop combinatori therapi
point discuss
checkpoint uniqu busi strategi partial de-risk pipelin
checkpoint therapeut focus develop immuno- target oncolog
treatment compani pipelin born variou licens deal purpos
develop commerci immune-enhanc combin involv
chemotherapi treat solid tumor checkpoint model primarili focus develop
drug valid target parp egfr approv therapi
compani also novel target pipelin bet gitr caix checkpoint
turn follow clinic develop path laid compani order potenti
gain regulatori approv product approv compani plan compet
price help gain market share ultim checkpoint goal becom one-stop
provid combin therapi treatment certain cancer
complet dose escal phase studi follow
initi expans cohort
potenti clinic updat phase trial
initi phase global registr trial
initi phase studi mutant egfr posit nsclc
analyst certif disclosur pleas see page
potenti efficaci data inhibitor checkpoint lead asset current
develop treatment non-smal cell lung cancer nsclc fulli human antibodi target
program cell death ligand express tumor cell block interact
cognat receptor interact mediat inhibitori signal neg regul anti-cancer activ effector
cell therapi target axi demonstr activ across wide rang cancer indic
includ nsclc melanoma renal cell carcinoma rcc hepatocellular carcinoma urotheli carcinoma
other inhibit axi lead enhanc cell prolifer cytokin chemokin product
tumor kill activ effector cell also abl carri anti-tumor effect induc antibodi
depend cell-medi cytotox adcc natur killer nk cell approv
antibodi merck kgaa nyse bavencio avelumab abil induc
current evalu phase dose escal studi immun checkpoint inhibitor nave patient
sever form cancer compani expect complet dose escal first quarter follow
expans cohort gener efficaci data note checkpoint phase studi includ site
australia new zealand checkpoint inhibitor therapi yet becom standard care site
select strategi could lead quicker recruit evid activ sinc patient nave
immunotherapi studi success checkpoint plan initi global registr enabl studi high pd-
express nsclc first quarter
checkpoint opportun gener meaning sale crowd space
current approv therapi across type cancer approv would like face
intens competit therapi develop order mitig risk
checkpoint strategi revolv around establish competit price compar other space consid
sale therapi expect exceed billion even low market penetr could
gener meaning revenu checkpoint
recent deal involv bode checkpoint juli celgen celg acquir
beigen bgne tislelizumab million up-front plu roughli billion potenti mileston
well royalti futur sale time acquisit tislelizumab phase develop
notabl deal includ purchas phase antibodi
macrogen deal worth million deal highlight continu interest
therapeut class checkpoint shown favor preclin result demonstr similar
bind affin compar fda approv therapi
gener egfr inhibitor follow tagrisso osimertinib clinic develop path ck-
third-gener epiderm growth factor receptor egfr tyrosin kinas inhibitor tki treatment
egfr-mut nsclc egfr mutat approxim nsclc case early-gener egfr
tki readili use treatment nave egfr mutant nsclc patient howev patient invari
progress therapi due resist mutat within egfr name mutat occur roughli
resist case astrazeneca tagrisso osimertinib third-gener small molecul inhibitor
approv treatment patient egfr -resist mutat
clinic develop support preclin data show anti-canc activ anim model
egfr-mut nsclc drug current evalu dose-escal phase studi patient
egfr-mut nsclc checkpoint expect provid clinic updat trial follow
initi phase ii studi confirm safeti efficaci compani plan initi phase trial
use similar design use astrazeneca tagrisso
checkpoint asset complement strategi build proprietari combin checkpoint
development plan involv pursu combin strategi in-hous immuno-oncolog candid
target compound checkpoint sever candid product portfolio potenti amen
combin regimen includ formal poli adp-ribos
polymeras parp enzym inhibitor licens teva pharmaceut nyse teva
bromodomain extra-termin bet protein inhibitor agonist glucocorticoid-induc tnfr
third quarter financi third quarter end septemb report
net loss million per share compar net loss million per share
period research develop expens million compar million third
quarter end septemb gener administr cost million third quarter
compar period septemb checkpoint million
cash cash equival
march checkpoint close public offer share common stock per share
compani expect receiv gross proce offer exclud underwrit discount
commiss offer relat expens checkpoint also grant underwrit option
purchas share common stock public offer price over-allot fulli exercis gross
fortress biotech relationship checkpoint found fortress biotech fbio hold
super-major posit subsidiari busi model fortress gain valu three-fold
fortress receiv fully-dilut outstand equiti annual subsidiari
fortress receiv futur revenu subsidiari
fortress receiv annual consult fee fee increas million annual
subsidiari hold net asset excess million begin calendar year
tabl content
preclin studi
target treatment solid tumor includ nsclc
inhibitor develop
clinic data discuss
on-going phase trial advanc cancer
overview nsclc
symptom diagnosi treatment option
approv oral egfr kinas inhibitor treatment nsclc
market inform egfr-mut nsclc
on-going phase i/ii trial egfr-mut nsclc
competit landscap drug develop mutant egfr nsclc
remain candid bolster checkpoint pipelin align strategi
risk invest
checkpoint therapeut biopharmaceut compani primarili focus develop
immuno- target oncolog treatment compani strategi revolv around acquir develop
commerci immune-enhanc combin involv chemotherapi treat solid tumor
compani lead asset fulli human antibodi target program cell death ligand
initi develop treatment option front-lin lung cancer compani plan develop
drug monotherapi addit solid tumor well combin asset pipelin shown
figur preclin studi show bind compar fda approv
inhibitor roch vtx rog vx astrazeneca nyse azn similar
pfizer/merck kgaa bavencio avelumab induc antibodi depend cell-medi cytotox adcc
inhibitor phase studi on-going evalu advanc oncolog indic
includ non-smal cell lung cancer nsclc compani expect complet dose escal portion
studi first quarter follow initi expans cohort provid initi efficaci data
second half global registr studi front-lin therapi high express
nsclc expect begin first quarter
addit checkpoint also develop gener irrevers inhibitor epiderm
growth factor receptor egfr treatment egfr mutat nsclc show anti-tumor activ
mutant egfr nsclc xenograft mous model limit activ -normal- wild type form
egfr notabl design specif activ egfr mutant
target astrazeneca tagrisso osimertinib time on-going phase i/ii studi evalu
egfr mutat posit nsclc compani plan announc clinic updat phase portion
trial plan begin phase follow clinic path use astrazeneca
develop tagrisso
checkpoint valu proposit root strategi in-licens immuno- target therapi
ultim goal establish combin treatment patient advanc tumor compani plan
employ build block combin therapi immun target drug
anti-glucocorticoid-induc tnfr-relat gitr antibodi well target therapi includ
gener egfr inhibitor poli adp-ribos polymeras parp inhibitor
bromodomain extra-termin bet protein inhibitor note compani subsidiari fortress biotech
fbio term relationship describ financi manag section
checkpoint develop fulli human antibodi target program cell death ligand
interact receptor mediat inhibitori signal neg regul anti-cancer activ
effector cell therapi target axi demonstr activ across wide rang cancer
carcinoma other cumul sale drug class roughli billion market
expect expand therapi becom cornerston treatment sever cancer preclin studi
shown bind compar level fda approv therapi also
shown abil induc antibodi depend cell-medi cytotox adcc approv anti-pd-
antibodi occur pfizer/merck kgaa bavencio avelumab compani initi phase studi
octob evalu checkpoint inhibitor nave patient sever form cancer expect
complet dose escal first quarter follow expans cohort gener efficaci data
year checkpoint also plan explor potenti combinatori approach in-hous portfolio candid
background normal condit program cell death ligand cognat receptor
essenti maintain immun cell toler inhibit autoimmun exampl tissu consid
immun privileg placenta testi anterior chamber eye express
site exogen antigen toler without induct immun respons mice genet ablat
either lead autoimmun symptom resembl lupus-lik arthriti glomerulonephr
type transmembran glycoprotein encod gene
constitut express low level rest lymphocyt antigen present cell apc bone-marrow
deriv mast cell outsid blood system also express lung vascular endothelium
mesenchym stem cell neuron pancreat islet cell among
express modul variou pathway suppress cell activ engag cognat
receptor cell interact lead recruit homolog
phosphatas caus dephosphoryl pkcq kinas result inhibit
et al ligand toler immun annu immunol
nishimura et al develop lupus-lik autoimmun diseas disrupt gene encod itim
wang et al role pathway immunolog privileg site reproduct
cell expans signal also inhibit mek/erk pathway import cell
express enhanc toll-lik receptor tlr mediat mek/erk activ tlr
subtyp non-catalyt receptor express antigen present cell apc play key role innat
immun system express also upregul interferon-g ifn-g receptor via
jak/sign transduc activ transcript stat pathway complement activ
mek/erk signal pathway cell express induc il-
ifn-g also shown upregul express
cancer context cancer engag cognat receptor result
inhibitori signal neg imping tumor-kil effect lymphocyt particular
overexpress tumor infiltr lymphocyt til tumor cell upregul express result
interact allow tumor cell escap immune-surveil activ cytotox lymphocyt variou studi
publish last decad shown inhibit axi clinic set result complet
durabl respons certain patient current develop
singl agent block interact enhanc anti-tumor effect tumor-kil cell
antibodi depend cell-medi cytotox adcc one way antibodi elicit anti-
cancer effect activ natur killer nk cell nk cell engag fc portion igg antibodi
display cell surfac fcgriiia receptor fcg receptor glycoprotein belong
immunoglobulin superfamili cross-lig fcgriiia igg result secret cytokin ifng
degranul nk cell induc cell monoclon antibodi use adcc
demonstr clinic activ across varieti diseas indic key aspect antibodi abil bind
antigen time induc immun effector function recruit immun cell
approv antibodi bavencio abil induc adcc although unclear time
featur result augment anti-canc effect checkpoint fulli human
antibodi retain abil induc adcc
mechan action fulli human monoclon antibodi direct
express tumor cell block interact shown figur inhibit
interact blue antibodi lead enhanc cell prolifer cytokin chemokin product tumor
kill activ bound tumor also abl elicit adcc though interact
fcgriiia express nk cell
ritprajak et al intrins extrins control express immunoregulatori molecul epitheli
cell squamou cell carcinoma oral oncolog
chen et al regul novel role pro-surviv signal cancer ann oncol
jenkin et al mechan resist immun checkpoint inhibitor
powl et al anti-program cell antibodi treatment urotheli
carcinoma state-of-the-art futur develop clinic genitourinari cancer doi
figur mechan action
modifi powl et al lifesci capit
preclin studi
vitro bind assay checkpoint perform seri vitro biochem assay investig
bind affin antibodi demonstr high affin human monkey
two separ vitro studi first studi use indirect enzym link immunosorb assay elisa determin
bind affin coat plate incub increas concentr ck-
durvalumab orang merck kgaa nyse bavencio avelumab yellow low-
affin control teal normal igg control green plate subsequ incub
enzyme-link secondari antibodi incub substrat lead emiss light captur
detect devic y-axi quantifi intens reaction surrog bind x-axi
logarithm base antibodi concentr shown figur tecentriq bavencio low affin
control lesser extent imfinzi similar bind affin compar
checkpoint also compar abil blue engag posit cell vitro compar tecentriq
red imfinzi orang bavencio yellow low affin antibodi teal posit cell separ
incub increas concentr antibodi sort use fluoresc activ cell sort
fac y-axi repres number posit cell x-axi repres logarithm base
antibodi concentr right panel figur show blue similar bind affin
fda approv antibodi red orang yellow compani also measur bind kinet
drug human monkey compar tecentriq display
tabl bottom figur togeth data suggest similar kinet profil
approv antibodi potenti read activ
compani present lifesci capit
function t-cell bioassay checkpoint examin abil inhibit
interact use well-us luciferase-bas bioassay assay nuclear factor activ cell nfat gene
regulatori element fuse luciferas report order measur cell activ nfat activ occur
jurkat engin cell artifici antigen present cell engag cell receptor tcr
activ interact nfat transcript luciferas activ inhibit ligat absenc
block antibodi presenc block antibodi luciferas level recov virtu tcr
signal figur show result blockad bioassay use blue tecentriq red imfinzi
orang bavencio yellow low affin antibodi teal normal igg control y-axi measur
nfat activ function antibodi concentr label x-axi show similar inhibitori
activ fda approv antibodi red orang yellow contrast low affin
normal igg control antibodi lower absent block activ togeth data support
clinic develop
figur activ blockad bioassay
induc adcc function fc domain make capabl induc antibodi
depend cell-medi cytotox adcc order assess whether fc domain abl induc
adcc express tumor cell pbmc differ donor incub su-
cell presenc either control igg hour level cytotox measur
use lactos dehydrogenas ldh releas assay ldh rapidli releas upon damag cell membran
figur show result two experi use differ donor addit cell mixtur lead
increas cytotox compar control poster present american associ
cancer research gener meet compani report adcc activ compar
bavencio tecentriq imfinzi expect limit adcc
figur adcc activ
gorelik et al preclin character novel fulli mab gener meet
target treatment solid tumor includ nsclc
establish valid immuno-oncolog target base signific durabl respons
phase ii/iii studi current approv therapi clinic approv oncolog
indic variou studi suggest express may prognost factor sinc overexpress
associ poor cancer indic overexpress correl greater
respons treatment togeth highlight prognost factor therapeut target
recent studi shown tumor mutat burden also good correl immunogen durabl
respons immunotherapi note checkpoint current evalu phase studi
varieti cancer indic includ nsclc
express across cancer type mention interact lead
inhibitori signal thwart immun surveil activ cytotox cell express
tumor detect across variou cancer lesser degre tumor infiltr immun cell roughli
nsclc sampl tumor biopsi infiltr immun cell
express shown predictor respons antibodi keynote-
studi merck nyse keytruda pembrolizumab higher tumor express
associ better progression-fre surviv overal surviv os respons rate
solid tumor preval posit tumor vari patient group melanoma
express strongli correl braf- mutat statu predictor poor prognosi melanoma patient
tumor overexpress experienc respons rate head neck squamou cell
carcinoma hnscc overexpress case patient tumor express high level
poor outcom respons rate treatment biomark analysi across cancer
valid therapeut target suggest may act prognost marker diseas outcom
interestingli durabl respons shown neg melanoma note lesion biopsi
test suggest express may predict marker respons treatment may
also depend factor tissu type
mutat landscap sensit immun checkpoint inhibitor immunotherapi shown
efficaci tumor type histor difficult treat howev signific proport
patient cancer respond therapi tumor associ antigen taa form result
mller et al prognost biomark head neck squamou cell carcinoma oncotarget
okita et al overexpress partial regul patient non-smal cell lung cancer cancer immunol
hino et al tumor cell express program cell ligand cancer
herbst rs et al pembrolizumab versu docetaxel previous treat advanc non-smal cell lung
scheel et al express non-smal cell lung cancer correl genet alter oncoimmun
daud et al program cell death-ligand express respons anti-program death antibodi
pembrolizumab melanoma clin oncol
jiang et al activ mapk melanoma cell resist braf inhibit promot express
revers mek inhibit clin cancer
non-synonym mutat call neoantigen uniqu tumor type correl cell
anti-canc activ sensit immun checkpoint blockad variou studi show cancer high
mutat burden increas format neoantigen recogn immun studi
link high mutat burden durabl clinic benefit figur present analysi
tumor mutat burden across variou cancer type focus indic checkpoint tri
address note skin squamou cell carcinoma case mutations/mb repres
rel high mutat burden import given checkpoint may includ indic expans
cohort phase studi
figur percentag tumor mutat burden mutations/mb
head neck squamou cell carcinoma hnscc
lifesci capit chalmer et al
dudley et al microsatellit instabl biomark blockad clin cancer
rizvi et al mutat landscap determin sensit blockad non-smal cell lung cancer scienc
data present base analysi use data deriv chalmer et al analysi human
cancer genom reveal landscap tumor mutat burden genom medicin
epidemiolog checkpoint could potenti use across variou indic howev compani
expect enrol immunotherapi nave nsclc cutan squamou cell carcinoma cscc patient
plan registr trial base estim american cancer societi case nsclc
diagnos us develop first-lin therapi nsclc patient case
surgic resect cur option patient approxim present metastat diseas
time diagnosi suggest roughli patient would potenti candid first-lin
cscc high incid overal prognosi result pauciti studi primarili due
high cost associ track diseas howev one studi estim patient
diagnos cscc develop nodal metastasi translat approxim
patient diagnos advanc diseas
checkpoint inhibitor market current therapi approv across variou cancer
indic shown figur sale opdivo keytruda tecentriq grown steadili reach billion
billion astrazeneca nyse azn imfinzi approv bladder cancer
fda approv supplement biolog licens applic sbla treatment stage unresect
nsclc bavencio approv merkel cell carcinoma bladder cancer imfinzi approv
bladder cancer nsclc earli result sale drug reflect
figur world-wide sale approv checkpoint inhibitor
molina et al non-smal cell clung cancer epidemiolog risk factor treatment survivorship mayo clinic
kaira et al cutan squamou cell carcinoma estim incid diseas nodal metastasi death
diseas unit state dermatol
colorect cancer head neck cancer
head neck cancer bladder cancer
head neck cancer
head neck cancer hepatocellular liver
brain cancer malign glioma aa gbm
market inhibitor expect exceed billion due increas approv
indic adopt figur show indic inhibitor approv current
phase studi tabl show sever overlap indic may result market fragment
increas competit patient due perceiv similar bavencio would expect
therapi eventu approv indic assum studi done approv
conduct similar design
figur on-going phase studi approv therapi
potenti success sale crowd checkpoint inhibitor market approv would
late entrant crowd field drug target pathway mention glut pd-
variou stage develop next section order compet checkpoint strategi revolv
around establish competit price compar other space even low penetr market
expect exceed billion could repres signific market opportun checkpoint exampl
market penetr billion market would repres million annual sale effect
seen vegf inhibitor sever achiev success sale indic
inhibitor develop
broad potenti inhibitor cornerston therapi across variou cancer indic led flurri
development activ particular drug class also sever licens deal mani player
biopharmaceut space aim develop combinatori treatment strategi incorpor
checkpoint inhibit current combin studi inhibitor on-going
figur show non-approv asset clinic develop variou malign includ
partner whether evalu combin anoth agent
figur inhibitor clinic develop
cancer blood cancer rcc
bla
pharma player look secur asset present potenti licens opportun
inhibitor quickli becom standard care variou cancer indic start point
combin strategi design enhanc durat respons promis therapi evid
string recent licens deal includ celgen celg acquisit beigen
bgne tislelizumab million up-front plu roughli billion potenti mileston well royalti
futur sale time deal tislelizumab phase develop treatment advanc
recent purchas phase antibodi
deal worth million
size deal highlight appetit among biopharmaceut compani acquir therapi target pd-
also valid pathway becom core treatment option cancer checkpoint shown
preclin activ compar clinic valid inhibitor current evalu
phase studi select tumor indic approv therapi show efficaci checkpoint expect
complet dose escal first quarter follow initi global registr enabl
studi end
order identifi potenti partner checkpoint screen large-cap pharma compani could
benefit partner inhibitor complement immuno-oncolog and/or targeted-oncolog asset
criteria use analysi includ market valu cash invest absenc late stage
candid figur show result analysi
figur larg cap pharma compani may benefit partnership
clinic data discuss
evalu monotherapi open-label phase dose escal studi patient advanc
solid tumor yet receiv immunotherapi checkpoint expect complet dose escal first
quarter follow enrol expans cohort gener initi efficaci data phase studi
evalu safeti overal respons rate orr checkpoint plan provid clinic updat
first half addit updat throughout
on-going phase trial advanc cancer
trial design first-in-human open-label phase dose escal studi examin
immunotherapi nave patient studi enrol patient non-smal cell lung cancer nsclc small cell
lung cancer sclc malign pleural mesothelioma mpm head neck squamou cell carcinoma hnscc
melanoma merkel cell carcinoma mcc renal cell carcinoma rcc urotheli carcinoma hodgkin lymphoma
studi consist three portion enrol patient screen day subsequ treat iv ck-
cycl dose escal portion studi compani may includ addit patient
character safeti efficaci select dose and/or specif patient popul
primari endpoint dose limit toxic treatment emerg advers event teae notabl secondari
endpoint includ best overal respons bor overal respons rate orr measur everi week first
week everi week studi complet trial also readout durat respons dor per
respons evalu criteria solid tumor recist version compani expect complet dose escal
first quarter follow initi expans cohort initi clinic updat studi
expect first half
studi success checkpoint initi global registr enabl studi high express nsclc
first quarter compani initi strategi obtain approv
monotherapi order gener revenu compani ultim strategi make cornerston
treatment explor combin use portfolio candid
path market inhibitor laid other checkpoint need replic checkpoint
model base develop drug valid target approv therapi compani turn follow
clinic develop path laid compani order potenti gain regulatori approv approv
part puzzl given checkpoint would ultim like becom one-stop provid combin
therapi treatment certain cancer point expand upon later section frame refer
approv merck keytruda pembrolizumab second-lin nsclc summar follow therapi
approv second-lin treatment option nsclc patient follow failur platinum chemotherapi
approv support phase ii/iii data show signific increas overal surviv month vs
month median progression-fre surviv mpf month vs month patient treat
mg/kg keytruda compar docetaxel patient keytruda subsequ
approv first-lin treatment patient express base posit data popul
checkpoint shown compar affin compar approv
therapi compani expect follow similar clinic develop plan merck develop
keytruda note checkpoint conduct phase studi australia new zealand region
checkpoint inhibitor therapi yet becom standard care site select strategi could lead
quicker recruit evid activ sinc patient nave immunotherapi look forward
orr data nsclc give indic viabil candid
checkpoint equip compet immunotherapi combin landscap combin
approach use immunotherapi expect becom standard treatment option futur enthusiasm
approach evidenc number on-going combin studi agent exce
checkpoint posit compet combin space divers portfolio immuno-
target therapi introduc later report moreov compani access wide varieti
candid develop compani fortress biotech fbio umbrella
remind fortress major sharehold founder checkpoint
enorm effort develop variou combinatori strategi inhibitor
approv combin agent bristol-my squibb nyse yervoy ipilimumab chemotherapi
exampl late stage combin asset clinic develop includ indoleamin
dioxygenas enzym inhibitor epacadostat phase i/ii studi combin epacadostat merck
keytruda second-lin treatment patient advanc tumor orr nsclc patient treat
combin roughli although note caution taken perform comparison
studi orr compar favor observ keytruda monotherapi keynote-
combo approach garner much attent given approv bristol-my squibb
opdivo plu yervoy treatment metastat melanoma although note seriou advers event
associ combin regimen announc juli phase mystic studi evalu
imfinzi tremelimumab -an therapy- fail meet primari endpoint use first-
line treatment nsclc co-primari endpoint overal surviv reach yet data expect
first half recent bristol-my squibb announc februari studi
evalu opdivo plu yervoy met endpoint first-lin nsclc patient high tumor mutat burden
note endpoint chang origin target popul posit cancer believ
checkpoint valu proposit may bolster divers pipelin could provid flexibl
come develop combinatori treatment oncolog
larg market cutan squamou skin carcinoma cutan squamou cell carcinoma cscc
second common skin cancer melanoma approxim case diagnos
standard care patient advanc cscc treatment option limit repres area high
unmet medic need mention earlier report cscc one highest mutat burden report
herbst rs et al pembrolizumab versu docetaxel previous treat advanc non-smal cell lung
cancer case mutations/mb recent find regeneron
sanofi nyse sni partner phase studi evalu cemiplimab inhibitor patient
advanc cscc show posit sign activ investig assess orr treat patient
includ complet respons cr partial respons pr term safeti common
trae fatigu interestingli appar associ orr express
support recent view tumor mutat burden better predictor respons checkpoint inhibit
note checkpoint could repres potenti treatment option patient cscc
moment less crowd nsclc market
checkpoint outlin potenti registr singl arm studi patient compani
mention like measur overal respons rate orr therapi primari endpoint trial
note time cost need complet propos trial could lower given orr primari
endpoint allow quicker readout
checkpoint develop third-gener epiderm growth factor receptor egfr tyrosin kinas inhibitor
tki also known treatment egfr-mut nsclc egfr mutat roughli
nsclc target first second-gener inhibitor shown increas progress free
surviv treatment nave egfr mutant nsclc patient howev patient invari progress due
resist mutat within egfr mutat common alter found patient
develop resist first second-gener egfr tki fact mutat found roughli
patient astrazeneca tagrisso osimertinib third-gener small molecul inhibitor design
specif target egfr-sensit egfr -resist mutat limit activ
clinic develop support preclin data show treatment limit cell prolifer
anim model egfr-mut nsclc limit activ cell overexpress normal egfr drug
current evalu dose-escal phase studi patient egfr-mut nsclc checkpoint
expect provid clinic updat trial follow initi phase ii studi confirm
safeti efficaci compani plan initi phase trial use similar design use
astrazeneca tagrisso mention checkpoint purs valid target egfr sinc may acceler
path approv help compani build pipelin allow combin approach
therapeut agent pipelin
mechan action oral administ gener coval irrevers egfr tki
specif target egfr-activ resist mutat includ del mutat
therapi limit activ wild type egfr thought caus skin rash diarrhea side effect
current evalu phase studi patient advanc solid tumor target egfr
appropri egfr mutant nsclc
kobayashi et al egfr mutat resist non-smal cell lung cancer gefitinib nejm
ko et al egfr reveal secret gatekeep lung cancer
select inhibit mutant-egfr cell checkpoint measur activ vitro cultur
cell model figur show result vitro prolifer assay similar astrazeneca tagrisso
osimertinib abil inhibit growth egfr mutant nsclc cell line far
potent boehring ingelheim privat afatinib irrevers inhibitor erbb famili receptor
tyrosin kinas rtk assay measur concentr drug need inhibit cell growth
low concentr drug therefor prefer suggest increas sensit cell drug
cell line harbor exon delet egfr nm compar
nm tagrisso nm afatinib inhibit growth cell degre tagrisso
afatinib import given epidermoid carcinoma cell line express high level wild
type egfr suggest may cleaner safeti profil tagrisso whole result suggest
similar activ tagrisso context target mutant egfr limit activ toward wild
figur cancer cell line prolifer assay
dose depend anti-canc activ murin model nsclc compani perform seri
experi evalu anti-canc effect mous model nsclc balb/c nude mice receiv
cell xenograft treat afatinib vehicl period cell
deriv nsclc tumor harbor egfr mutat mice receiv daili
oral dose rang mg/kg- mg/kg red green purpl mg/kg afatinib blue vehicl
control black figur show dose-depend tumor limit effect green purpl compar
vehicl control treat afatinib treat mice
figur activ nsclc xenograft mous model
limit activ wild type egfr checkpoint investig whether activ
wild type -normal- egfr second gener lesser degre third gener egfr tki
tagrisso shown activ normal egfr inhibit wild type egfr associ
caus rash diarrhea patient receiv tagrisso phase studi nsclc experienc diarrhea rash
decreas appetit nausea may attribut inhibit wild type
side-effect highlight need third gener egfr tki cleaner safeti profil retain anti-
cancer activ mutant egfr drug toler safeti profil may amen combin
therapi often plagu unwant side-effect
babl/c nude mice receiv cell egfr overexpress xenograft separ treat increas
dose afatinib vehicl use dose scheme describ anim receiv dose
rang mg/kg- mg/kg red green purpl mg/kg afatinib blue vehicl control black figur
show effect tumor growth time compar afatinib vehicl control treat anim
activ wild type egfr tumor evidenc similar growth curv
vehicl treat anim contrast afatinib treat mice show greater anti-tumor activ wild type
egfr tumor suggest may less skin toxic patient maintain anti-canc activ
mutant egfr nsclc note compani evalu effect tagrisso prolifer
particular cell line could give indic compar context
jnne et al egfr inhibitor- resist non-small-cell- lung cancer nejm
figur activ wild type egfr express cell
overview nsclc
nsclc one common form cancer estim patient us diagnos
diseas die similar type lung cancer nsclc predomin caus
tobacco smoke howev risk factor includ exposur radon asbesto certain chemic air pollut
radiat treatment lung arsen drink water genet predisposit
checkpoint focus develop egfr-mut nsclc case potenti
combin compani antibodi indic compani current
develop phase studi patient mutat egfr plan follow phase ii studi
patient popul
nsclc account approxim lung cancer adenocarcinoma largest group
repres case compar small-cel lung carcinoma nsclc tend grow slowli
earli detect cur surgic resect higher probabl success accord nation cancer
institut surviv rate local region distant nsclc tumor
adenocarcinoma squamou cell character genet alter includ somat gene mutat copi
number alter chromosom rearrang util therapeut target
adenocarcinoma often distinguish mutat drive enhanc signal receptor tyrosin
kinase/ras/raf signal pathway gene includ egfr kra braf mutat
tumor suppressor gene activ mutat egfr often
link squamou cell lung figur show rel distribut differ cancer-
devearakonda et al next-gener sequenc lung cancer lesson learn futur direct hematolog oncol north
drive mutat identifi patient lung adenocarcinoma checkpoint target
specif mutat egfr present lung adenocarcinoma
figur molecular subset lung adenocarcinoma
symptom diagnosi treatment option
earli stage nsclc initi caus notic symptom eventu patient experi persist
cough troubl breath constant chest pain patient present symptom subject
biopsi diagnost test cancer diagnosi confirm via biopsi addit test may perform
determin stage nsclc stage assess accord tnm classif system develop
intern union cancer iuac recommend american joint committe cancer ajcc
tnm stage criteria divid nsclc five stage use determin appropri treatment option
stage base degre metastasi
treatment nsclc stage depend diseas identifi earli surgic resect tumor
often treatment need figur provid gener overview major treatment option patient
differ stage nsclc stage iv patient advanc point cancer spread
organ therapi target secondari metastas indic patient often prescrib rtk
inhibitor inhibitor /- chemotherapi chemotherapi alon sever rtk drug current avail
nsclc includ limit follow
egfr inhibitor tarceva erlotinib iressa gefitinib tagrisso osimertinib
inhibitor xalkori crizotinib zykadia ceritinib alcensa alectinib alunbrig brigatinib
inhibitor becom import treatment option line nsclc indic
use follow progress egfr inhibitor patient tumor harbor one genet
alter checkpoint plan explor potenti synergi antibodi
figur treatment option differ stage nsclc
degre metastasi
cancer spread beyond inner
line lung
cancer small spread
surgeri possibl chemotherapi
lymph node
cancer spread lymph
cancer spread nearbi tissu
distant lymph node
cancer spread organ
surgeri surgeri adjuv
surgeri surgeri adjuv
chemotherapi radiat
approv oral egfr kinas inhibitor treatment nsclc
develop path nsclc shift strategi target broad patient popul identifi
patient like succeed base molecular characterist best exemplifi approv
egfr inhibitor timelin approv greatli acceler xalkori approv
year launch phase trial discoveri molecular rearrang target compar
approxim year typic cancer therapeut
first gener egfr inhibitor commerci success treatment option egfr mutant
subgroup nsclc howev chronic use often result acquir resist due threonin methionin
mutat posit egfr gatekeep mutat found approxim
biopsi patient receiv egfr inhibitor therapi led develop
gener egfr inhibitor sinc gener inhibitor show limit efficaci mutat
third-gener inhibitor design target egfr- sensit -resist mutat
limit activ wildtyp -normal- egfr therebi curb side-effect associ
-gener egfr inhibitor tagrisso gener irrevers inhibitor approv
therapi show object respons rate month progress free surviv egfr inhibitor resist
nsclc patient common diarrhea rash decreas appetit nausea
kobayashi et al egfr mutat resist non-smal cell lung cancer gefitinib nejm
ko et al egfr reveal secret gatekeep lung cancer
recent data present esmo show orr month use
tagrisso first-lin therapi egfr-mut nsclc fda recent accept snda drug
first-lin set result expect tagrisso eventu becom standard care first-lin egfr mutant
nsclc drug gener million sale first month expect gener
approxim billion sale checkpoint gener irrevers inhibitor activ
low activ wild type egfr may translat better toler compar tagrisso
market inform egfr-mut nsclc
egfr mutat nsclc epidemiolog base estim american cancer societi case
nsclc diagnos us develop first-lin salvag therapi nsclc
patient egfr mutat tumor alter egfr make roughli nsclc translat
target popul new patient us year gatekeep mutat thought
respons resist first gener egfr inhibitor roughli approxim
nsclc patient region distant diseas time diagnosi may becom candid treatment
local diseas relaps could becom
elig
market opportun checkpoint develop patient nsclc harbor egfr mutat
tagrisso approv egfr-mut nsclc carri mutat progress egfr
tyrosin kinas inhibitor therapi fda accept snda drug line treatment patient
metastat egfr-mut nsclc sever compet gener egfr inhibitor develop
like sever reach market address market us patient egfr
mutant nsclc either salvag treatment up-front treatment outlin
popul estim peopl us diagnos nsclc
harbor egfr mutat region metastat diseas time
diagnosi local diseas relaps could becom elig first line
treatment translat patient per year us checkpoint also target patient
acquir gatekeep result front-lin egfr tki use mutat acquir
patient amount patient
due potenti addit effect egfr inhibit checkpoint plan explor combin
plu compani therapi approach line checkpoint strategi build
proprietari combin product use backbon therapi
potenti meaning sale midst competit current egfr tki approv
treatment egfr mutant nsclc sale lead drug depict figur amount roughli
billion tarceva patent set expir novemb could lead decreas market
jnne et al egfr inhibitor- resist non-small-cell- lung cancer nejm
yu et al analysi tumor specimen time acquir resist egfr-tki therapi patient
egfr-muant lung cancer clinic cancer
uramoto tanaka recurr surgeri patient nsclc translat lung cancer research
share due entranc gener tagrisso gener egfr inhibitor approv patient progress
diseas first-lin egfr tki treatment drug receiv prioriti review front-lin set
increas address market approv would like face strong competit tagrisso howev
show similar profil tagrisso checkpoint could potenti compet price may still
result meaning sale furthermor compani could gain advantag offer second drug
part combinatori treatment regimen scenario key checkpoint strategi develop first-in-
class combin product refer annual wac tagrisso averag
figur sale approv therapi egfr-mut nsclc
potenti market enhanc respons blockad nsclc patient checkpoint
inhibitor like bristol-my squibb opdivo yervoy merck keytruda becom import treatment
option sever form cancer although effect compar convent therapi respons rate immun
checkpoint blockad often low mani cancer indic therapeut option limit follow
progress checkpoint develop monotherapi also plan explor combin approach
immuno- target therapi case nsclc checkpoint plan evalu plu ck-
note studi address combin regimen encount may limit approach
initi rational egfr checkpoint blockad combin base preclin studi show
oncogen egfr signal lead upregul express escap immun surveil
blockad egfr-mut tumor mous model slow tumor growth significantli increas overal surviv
inhibit egfr also thought upregul mhc express increas inflamm
akbay et al activ pathway contribut immun escap egfr-driven lung tumor cancer
may play role immun cell current inhibit approv nsclc follow
progress egfr inhibitor
hypothesi combin egfr tki therapi would lead increas and/or durabl
respons test multipl clinic studi phase ib studi evalu imfinzi plu tagrisso egfr tki
nave patient harbor egfr mutant tumor show overal respons rate orr combin
howev note treatment coupl greater includ occurr interstiti lung diseas
ild led discontinu studi studi use similar treatment regimen also
encount treatment relat includ elev liver enzym moment unclear whether ck-
combin abl circumv howev drug combin abl show
increas orr clean safeti profil strategi could repres potenti therapeut option nsclc
checkpoint complet seri preclin studi help back clinic develop egfr-
mutant nsclc dose-escal phase studi began octob therapi receiv
orphan drug design treatment egfr-mut nsclc novemb checkpoint expect
provid clinic updat studi compani also plan initi phase ii studi egfr-
mutant nsclc later year well phase registr trial indic
on-going phase i/ii trial egfr-mut nsclc
trial design first-in-human open-label phase i/ii studi oral patient advanc solid
tumor target egfr may appropri egfr mutant nsclc patient studi
conduct two part phase portion enrol patient receiv escal dose oral
administ daili cycl primari endpoint portion studi incid dose-limiting-
phase ii portion studi enrol patient mutant nsclc fail treatment
first-lin egfr inhibitor patient expect receiv recommend phase ii dose oral
daili primari endpoint studi object respons rate orr defin complet
respons cr partial respons pr per recist notabl secondari endpoint includ diseas control rate
dcr durat respons progress free surviv checkpoint expect provid clinic updat
phase studi follow initi phase ii studi confirm safeti efficaci
compani also plan initi phase studi follow similar trial design use tagrisso
approv data readout phase trial expect approxim year initi
pollack egfr inhibitor mhc express immun respons oncoimunnolog
competit landscap drug develop mutant egfr nsclc
initi develop treatment nsclc patient egfr -activ resist mutat
first-lin egfr inhibit astrazeneca tagrisso approv novemb egfr mutant
patient progress prior egfr tki therapi drug show orr diseas
control rate patient tumor harbor mutat therapi recent receiv prioriti review
grant breakthrough design btd first-lin treatment patient metastat egfr mutant
nsclc treatment evalu compani sponsor trial egfr mutant nsclc depict
figur checkpoint aim recapitul respons rate seen tagrisso order follow similar clinic
develop path note show desir efficaci on-going phase i/ii studi
checkpoint could path registr trial end compani estim studi could
take approxim month complet would put close competit hanmi pharma krx
olimutinib expect initi global phase studi first half also note
nyse recent announc expect advanc file irrevers pan-her tyrosin
kinas inhibitor dacomitinibib file base find archer studi met
primari endpoint signific median progress free surviv compar astrazeneca nyse azn iressa
gefitinib month vs month hr note dacomitinib less toler
gefitinib mani patient requir dose
use gener egfr tki tagrisso lesser degre associ signific skin
toxic due activ normal egfr toler profil may advantag tagrisso
drug develop may lower activ wild type egfr preclin studi
shown limit activ wild type egfr could translat lower skin toxic potenti
advantag tagrisso drug develop
term address popul could opportun also penetr first-lin egfr-mut
segment market mention earlier tagrisso recent receiv prioriti review indic given
similar mechan action believ popul potenti also serv
nsclc patient region metastat diseas time diagnosi repres sizabl portion
market could address target therapi whole sale acquisit cost wac tagrisso
per year per patient checkpoint believ may abl captur gener egfr
inhibitor market establish competit price potenti ad combin product
wu et al dacomitinib versu gefitinib first-lin treatment patient egfr-mutation-posit non-small-cel
phase
figur drug clinic develop egfr mutant nsclc
remain candid bolster checkpoint pipelin align strategi
addit lead candid checkpoint develop sever asset valid
target cancer advanc candid group formal poli adp-ribos
polymeras parp enzym inhibitor licens teva pharmaceut nyse teva shown
modest activ singl agent combin chemotherapi three separ studi treatment
solid tumor checkpoint current reformul plan initi phase ib studi drug
wu et al dacomitinib veru gefitinib first-lin treatment patient egfr-mutation-posit non-small-cel
tan et al first-in-human phase studi third gener mutant-select egfr tyrosin kinas
inhibitor advanc non-smal cell lung cancer nsclc harbor gener meet
park et al bi egfr mutant-specif inhibitor nsclc efficaci safeti
gener meet
han et al phase ii single-arm efficaci safeti studi pf poziotibnib korean patient
advanc metastat lung adenocarcinoma acquir resist epiderm growth factor receptor tyrosin kinas
follow success reformul compani also develop bromodomain extra-termin bet
protein inhibitor expect file ind first half remain candid checkpoint
portfolio antibodi includ agonist glucocorticoid-induc tnfr relat protein gitr
anti-carbon anhydras ix caix therapeut antibodi anti-caix therapi preclin
parp inhibitor checkpoint in-licens teva pharmaceut subsidiari
cephalon drug oral small molecul direct enzym current
develop solid tumor parp enzym play critic role repair singl strand dna break
base-excis repair pathway parp inhibitor recent garner enthusiasm medic commun given
shown strong activ monotherapi across multipl cancer indic defect dna repair
mechan includ tumor loss function alter enzym involv dna
repair inhibit parp tumor harbor brca mutat defici homolog recombin
mechan lead uncontrol accumul doubl strand dna break ultim induc cancer cell
death notabl vulner come function enzym compromis process
known synthet lethal
previous evalu separ clinic studi single-ag combin
chemotherapeut treatment solid tumor mantl cell studi show
activ combin either temozolomid gemcitabine/cisplatin combin includ
partial respons treat mg/day plu temozolomid treat mg bid
plu cisplatin gemcitabin complet respons treat mg bid plu cisplatin
gemcitabin patient stabl diseas treat mg bid plu cisplatin
gemcitabin howev exposur variabl across cohort myelosuppress observ
combin gemcitabin cisplatin limit activ observ combin
administ singl agent patient advanc metastat solid tumor induc stabl
diseas patient system exposur activ form drug variabl hinder definit
conclus respect efficaci
checkpoint plan evalu reformul drug order enhanc bioavail follow
phase ib studi advanc solid tumor indic exist dna repair defect alter
compani plan develop single-ag combin anti-canc
drug includ immuno- targeted-therapi astrazeneca nyse azn lynparza olaparib
rubraca rucaparib tesaro tsro zejula niraparib approv treatment
target parp sale parp inhibitor class first month total million
expect grow blockbust drug class note approv parp inhibitor parp
plummer et al phase dose-escal studi parp inhibitor monotherapi combin
temozolomid patient solid tumor cancer chemoth pharmacol
awada et al open-label dose-escal studi evalu safeti pharmacokinet
inhibitor combin gemcitabin cisplatin patient advanc solid tumor anti-cancer
trap effect trap parp enzym dna differ inhibit activ parp without
trap effect
bet inhibitor oral inhibitor bet protein bromodomain protein
so-cal reader recogn acetyl lysin epigenet modif present histon extens studi
shown deregul epigenet compon addit genet anomali play signific role
develop cancer block bind acetyl histon transcript
factor inhibit shown promis result preclin model cancer target c-myc express
myc-driven c-myc oncogen transcript factor estim overexpress
deregul approxim human cancer variou studi highlight select kill
cancer cell across broad rang blood malign certain solid current
program phase i/ii develop target bet protein treatment blood solid tumor
particular shown play role across variou hematolog solid tumor act coactiv
prolif gene note shown play role fibrosi repres anoth potenti applic
therapi outsid cancer checkpoint complet preclin studi plan submit
ind treatment variou advanc cancer first half
anti-gitr antibodi fulli human antibodi design bind gitr order enhanc
prolifer activ cytokin product posit t-cell rational target gitr
root preclin clinic studi show modul tumor microenviron key elicit
robust tumor respons particularli increas effector cell maintain high ratio effector cell
regulatori cell treg preclin studi shown gitr modul result antitumor activ due
costimulatori effect cell inhibit deplet treg expans treg
associ limit activ immunotherapi checkpoint anti-gitr antibodi design
elimin immunosuppress effect treg effector cell expans current candid target
gitr clinic develop includ bristol-my squibb nyse
inhibit suggest favor safeti profil potenti antitumor activ although single-arm
open label studi make unclear whether gitr agon boost activ therapi checkpoint
plan develop indic scientif literatur support possibl efficaci includ
nsclc renal cell carcinoma rcc preclin develop
anti-caix antibodi checkpoint licens world-wide right certain anti-carbon anhydras ix caix
antibodi dana farber current preclin develop checkpoint fulli human anti-caix
antibodi recogn caix express cell kill via adcc complement-depend cytotox cdc
demonstr preclin caix tumor associ antigen almost exclus
express renal cancer cell overexpress
delmor et al bet bromodomain inhibit therapeut strategi target c-myc cell
stathi et al result first-in-human phase trial assess oral avail bet-
bromodomain brd inhibitor advanc hematolog malign eur cancer
sahai et al target bet bromodomain protein solid tumor oncotarget
chang et al human anti-caix antibodi mediat immun cell inhibit renal cell carcinoma vitro
human mous model vivo
genega et al carbon anhydras ix express renal neoplasm correl tumor type grade
checkpoint obtain patent right major product in-licens figur show
compani patent portfolio includ licens patent number expiri date issu pend patent
anti-caix gener cover composit matter method treatment
grant us patent
unit
europ israel
earli
late
presid chief execut offic
mr oliviero nearli twenti year oper experi biotechnolog industri may
septemb mr oliviero serv varieti leadership capac keryx biopharmaceut inc publicly-
trade biotechnolog compani recent chief offic sinc april
instrument growth compani market capit billion tenur keryx mr
oliviero oversaw financ account investor relat corpor govern busi develop legal
matter well lead member design sever clinic studi regulatori oversight keryx
new drug applic auryxia success obtain fda market approv also gain
ema market approv also keryx mr oliviero complet million variou public financ
compani prior keryx august may mr oliviero director financ access
oncolog inc privately-held biotechnolog compani mr oliviero began profession career invest
banker ing bare furman selz new york citi mr oliviero cfa charterhold hold
financ highest distinct emori univers goizueta busi school
vice presid financ account princip financ offic
garrett gray serv vice presid financ account sinc februari princip
offic sinc decemb mr gray join checkpoint keryx biopharmaceut inc publicly-trad
biotechnolog compani join recent serv corpor control help
grow financ account depart keryx transit development-stag compani fulli
integr commerci organ prior join keryx mr gray began profession career deloitt
touch llp serv senior auditor mr gray bachelor scienc degre account
lehigh univers certifi public account state new york
relationship fortress biotech may allow effici drug develop
fortress biotech compani fortress close involv development progress product candid within
subsidiari compani shown figur includ provid fund manag servic regard
busi develop account financ clinic trial execut scientif affair manufactur legal
experienc board member addit fortress maintain super-major vote share subsidiari
mean fortress retain full control execut decis forward direct subsidiari process
allow effici drug develop checkpoint may result substanti cost save throughout
figur fortress fund manag support subsidiari compani
risk invest
consid invest checkpoint high-risk invest checkpoint develop
stage compani histori take treatment market current fda approv drug
portfolio compani program limit data date furthermor earli indic efficaci
necessarili translat posit late-stag result clinic trial result signific addit expens
compani may requir addit round dilut financ compani checkpoint may unabl
obtain suffici capit fund plan develop program regulatori risk associ
develop drug checkpoint may receiv fda approv candid despit signific time
financi invest regulatori approv market sell drug guarante drug penetr
market sale may meet expect
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
